Spironolactone
Product Images NDC 66336-916

4 FDA label images from Dispensing Solutions, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 66336-916). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0916-xx (Ndc 66336 0916 Xx Qualitest Pharmaceuticals)

Ndc 66336-0916-xx (Ndc 66336 0916 Xx      Qualitest Pharmaceuticals)
Spironolactone 25 mg tablets label by Dispensing Solutions, Inc., with product NDC 66336-0916. The label includes dosage form as tablets, lot number SAMPLE, expiration date 00-00, and prescription only notice. It features warnings to keep out of children's reach, storage instructions, and manufacturer information for Qualitest Pharmaceuticals Huntsville, AL. The label shows barcode and sample product details.*
FDA Label Image

This Is The Structual Formula For Spironolactone. (Spironolactonetabs 1)

This Is The Structual Formula For Spironolactone. (Spironolactonetabs 1)
Chemical structure of spironolactone showing its steroid-like core with attached functional groups. Molecular formula is C24H32O4S and molecular weight is 416.57.*
FDA Label Image

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)
A Kaplan-Meier survival curve chart comparing the probability of survival over months between Spironolactone and placebo groups. The chart shows two curves with patient numbers indicated (Spironolactone n=822, Placebo n=841) and includes a log-rank p-value of less than 0.001, illustrating statistical comparison over a timeline up to 48 months.*
FDA Label Image

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)
A forest plot illustrating hazard ratios (HR) with 95% confidence intervals (CI) across multiple subgroups for a trial comparing spironolactone versus placebo. The chart includes subgroups by age, sex, race, left ventricular ejection fraction (LVEF), heart failure status, diabetes, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use, displaying the number of participants (N) in each group. The horizontal axis ranges from 0.2 to 1.4, showing comparative effectiveness.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.